ME Therapeutics Holding Inc METXF
Trading Information
- Previous Close Price
- $3.25
- Day Range
- $1.67–1.67
- 52-Week Range
- $1.67–3.25
- Bid/Ask
- $1.63 / $1.63
- Shares Outstanding
- 30.05M
- Market Cap
- $50.18M
- Volume/Avg
- 999 / 900
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.metherapeutics.com
Valuation
|
Metric
|
METXF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 107.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
METXF
Financial Strength
|
Metric
|
METXF
|
|---|---|
Quick Ratio | 3.87 |
Current Ratio | 3.91 |
Interest Coverage | −172.46 |
Quick Ratio
METXF
Profitability
|
Metric
|
METXF
|
|---|---|
Return on Assets (Normalized) | −94.24% |
Return on Equity (Normalized) | −108.42% |
Return on Invested Capital (Normalized) | −104.90% |
Return on Assets
METXF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%s$th@W | LOCK|VT>^ | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@FC%jVh | LOCK|DLSL | $80B | |||
| argenx SE ADR
ARGX
| LOCK|#Pq#sk< | LOCK|YnD | $62B | |||
| Moderna Inc
MRNA
| LOCK|gfV$%# | LOCK|%<C | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xSS#L<j | LOCK|s< | $40B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vl$#Sz | LOCK|QBN>& | $33B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|c^p$%JX% | LOCK|H><k | $26B | |||
| Incyte Corp
INCY
| LOCK|<vNB!nN | LOCK|fq? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Rhmk$p | LOCK|l@ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|GTnN&>! | LOCK|Z^P | $16B |
United States